Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis

• Published in: Seminars in arthritis and rheumatism 2020-06, Vol.50 (3), p.509-514
• Main Authors: Campochiaro, Corrado, Tomelleri, Alessandro, Sartorelli, Silvia, Cavalli, Giulio, De Luca, Giacomo, Baldissera, Elena, Dagna, Lorenzo
• Format: Article
• Language: English
• Subjects: Adult; Anti-TNF; Antirheumatic Agents - therapeutic use; Biologic agents; Biological Factors - therapeutic use; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence - psychology; Medication Adherence - statistics & numerical data; Middle Aged; Retention rate; Retrospective Studies; Takayasu arteritis; Takayasu Arteritis - drug therapy; Tocilizumab; Treatment; Tumor Necrosis Factor Inhibitors - therapeutic use
• ISSN: 0049-0172; 1532-866X
• DOI: 10.1016/j.semarthrit.2020.01.005

We retrospectively investigated drug retention rate (DRR) and reasons for discontinuation of seven biologic disease-modifying anti-rheumatic drugs (bDMARDs) in Takayasu's arteritis (TA) in a real-world setting. TA patients followed-up in our center fulfilling the 1990 ACR criteria and treated with ≥1 bDMARD were selected. Data about disease duration, number of bDMARDs, reasons for bDMARDs discontinuation, and concomitant conventional synthetic (cs)DMARDs were collected. Survival curves were examined by the Kaplan-Meier method and compared using a stratified log-rank test. 24-month DRR was calculated. Hazard ratio (HR) for concomitant csDMARDs and for previous bDMARDs was evaluated. A comparative sub-analysis between anti-TNFα drugs and tocilizumab was performed. We identified 50 patients and 86 bDMARD-courses. No significant differences were observed in age and disease duration between the seven groups. Infliximab was the most frequent first-line bDMARD (78.6%). At bDMARDs initiation, all patients were prescribed prednisone (mean dose, 13.5 ± 10.3 mg/day) and 85.2% concomitant csDMARD therapy. 43% of treatment courses were stopped by 24 months. Golimumab had the highest DRR (71.4%), followed by infliximab (69%), adalimumab (56.3%), abatacept (50%), tocilizumab (41.1%), anakinra (0%) and rituximab (0%), p = 0.016. Concomitant csDMARDs therapy showed positive effects on DRR (HR=2.87, 95% CI=1.19–6.92, p = 0.019). Anti-TNFα drugs had significantly higher DRR compared to tocilizumab (67.2% vs 41.1%, p = 0.028). Even in these subgroups, csDMARDs showed positive effects on DRR (HR=3.79, 95% CI=1.49–9.6, p = 0.005). Anti-TNFα agents had the highest DRR overall and a higher DRR in a head-to-head comparison with tocilizumab. Concomitant csDMARDs had a significant positive effect on bDMARDs DRR.